Exact Mass: 471.1927
Exact Mass Matches: 471.1927
Found 500 metabolites which its exact mass value is equals to given mass value 471.1927
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PUROMYCIN
An aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium, that causes premature chain termination during translation taking place in the ribosome. C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D009676 - Noxae > D000963 - Antimetabolites C784 - Protein Synthesis Inhibitor D000970 - Antineoplastic Agents KEIO_ID P075; [MS2] KO009213 KEIO_ID P075
Dabigatran
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173066 - Direct Thrombin Inhibitor D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Hydroxydesmthyl doxepin glucuronide
Hydroxydesmthyl doxepin glucuronide is a metabolite of doxepin. Doxepin is a psychotropic agent with tricyclic antidepressant and anxiolytic properties, known under many brand-names such as Aponal, the original preparation by Boehringer-Mannheim, now part of the Roche group; Adapine, Doxal, Deptran, Sinquan and Sinequan. As doxepin hydrochloride, it is the active ingredient in cream-based preparations (Zonalon and Xepin) for the treatment of dermatological itch. (Wikipedia)
N-(4-(2-(2,3-Dihydrobenzo(b)furan-7-carboxamido)ethyl)benzenesulfonyl)-N'-cyclohexylurea
Dabigatran
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173066 - Direct Thrombin Inhibitor D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
5'-Guanidinonaltrindole
3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid
D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors
puromycin
Zanubrutinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents D006401 - Hematologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-hydroxy-3-methoxyphenylacetonitrile 4-O-alpha-L-rhamnopyranosyl(1->6)-beta-D-glucopyranoside|adenophoraside C
(13R)-6alpha,7beta-dihydroxy-8beta,13-epoxy-11beta-nicotinyloxy-ent-clerodan-3-en-15,16-olide|scutelinquanine D
Fluprostenol methyl amide
1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]
Ala His Met Asn
Ala His Asn Met
Ala Met His Asn
Ala Met Asn His
Ala Asn His Met
Ala Asn Met His
Cys Gly His Arg
Cys Gly Arg His
Cys His Gly Arg
Cys His Asn Val
Cys His Arg Gly
Cys His Val Asn
Cys Asn His Val
Cys Asn Val His
Cys Pro Pro Arg
Cys Pro Arg Pro
Cys Arg Gly His
Cys Arg His Gly
Cys Arg Pro Pro
Cys Val His Asn
Cys Val Asn His
Asp His Asn Ser
Asp His Ser Asn
Asp Ile Pro Gln
Asp Ile Gln Pro
Asp Leu Pro Gln
Asp Leu Gln Pro
Asp Asn His Ser
Asp Asn Ser His
Asp Pro Ile Gln
Asp Pro Leu Gln
Asp Pro Gln Ile
Asp Pro Gln Leu
Asp Gln Ile Pro
Asp Gln Leu Pro
Asp Gln Pro Ile
Asp Gln Pro Leu
Asp Ser His Asn
Asp Ser Asn His
Glu Ile Asn Pro
Glu Ile Pro Asn
Glu Leu Asn Pro
Glu Leu Pro Asn
Glu Asn Ile Pro
Glu Asn Leu Pro
Glu Asn Pro Ile
Glu Asn Pro Leu
Glu Pro Ile Asn
Glu Pro Leu Asn
Glu Pro Asn Ile
Glu Pro Asn Leu
Glu Pro Gln Val
Glu Pro Val Gln
Glu Gln Pro Val
Glu Gln Val Pro
Glu Val Pro Gln
Glu Val Gln Pro
Gly Cys His Arg
Gly Cys Arg His
Gly His Cys Arg
Gly His Lys Met
Gly His Met Lys
Gly His Met Gln
Gly His Gln Met
Gly His Arg Cys
Gly Lys His Met
Gly Lys Met His
Gly Met His Lys
Gly Met His Gln
Gly Met Lys His
Gly Met Gln His
Gly Gln His Met
Gly Gln Met His
Gly Arg Cys His
Gly Arg His Cys
His Ala Met Asn
His Ala Asn Met
His Cys Gly Arg
His Cys Asn Val
His Cys Arg Gly
His Cys Val Asn
His Asp Asn Ser
His Asp Ser Asn
His Gly Cys Arg
His Gly Lys Met
His Gly Met Lys
His Gly Met Gln
His Gly Gln Met
His Gly Arg Cys
His Lys Gly Met
His Lys Met Gly
His Met Ala Asn
His Met Gly Lys
His Met Gly Gln
His Met Lys Gly
His Met Asn Ala
His Met Gln Gly
His Asn Ala Met
His Asn Cys Val
His Asn Asp Ser
His Asn Met Ala
His Asn Ser Asp
His Asn Thr Thr
His Asn Val Cys
His Gln Gly Met
His Gln Met Gly
His Gln Ser Thr
His Gln Thr Ser
His Arg Cys Gly
His Arg Gly Cys
His Ser Asp Asn
His Ser Asn Asp
His Ser Gln Thr
His Ser Thr Gln
His Thr Asn Thr
His Thr Gln Ser
His Thr Ser Gln
His Thr Thr Asn
His Val Cys Asn
His Val Asn Cys
Ile Asp Pro Gln
Ile Asp Gln Pro
Ile Glu Asn Pro
Ile Glu Pro Asn
Ile Asn Glu Pro
Ile Asn Pro Glu
Ile Pro Asp Gln
Ile Pro Glu Asn
Ile Pro Asn Glu
Ile Pro Gln Asp
Ile Gln Asp Pro
Ile Gln Pro Asp
Lys Gly His Met
Lys Gly Met His
Lys His Gly Met
Lys His Met Gly
Lys Met Gly His
Lys Met His Gly
Leu Asp Pro Gln
Leu Asp Gln Pro
Leu Glu Asn Pro
Leu Glu Pro Asn
Leu Asn Glu Pro
Leu Asn Pro Glu
Leu Pro Asp Gln
Leu Pro Glu Asn
Leu Pro Asn Glu
Leu Pro Gln Asp
Leu Gln Asp Pro
Leu Gln Pro Asp
Met Ala His Asn
Met Ala Asn His
Met Gly His Lys
Met Gly His Gln
Met Gly Lys His
Met Gly Gln His
Met His Ala Asn
Met His Gly Lys
Met His Gly Gln
Met His Lys Gly
Met His Asn Ala
Met His Gln Gly
Met Lys Gly His
Met Lys His Gly
Met Asn Ala His
Met Asn His Ala
Met Pro Pro Gln
Met Pro Gln Pro
Met Gln Gly His
Met Gln His Gly
Met Gln Pro Pro
Asn Ala His Met
Asn Ala Met His
Asn Cys His Val
Asn Cys Val His
Asn Asp His Ser
Asn Asp Ser His
Asn Glu Ile Pro
Asn Glu Leu Pro
Asn Glu Pro Ile
Asn Glu Pro Leu
Asn His Ala Met
Asn His Cys Val
Asn His Asp Ser
Asn His Met Ala
Asn His Ser Asp
Asn His Thr Thr
Asn His Val Cys
Asn Ile Glu Pro
Asn Ile Pro Glu
Asn Leu Glu Pro
Asn Leu Pro Glu
Asn Met Ala His
Asn Met His Ala
Asn Asn Pro Gln
Asn Asn Gln Pro
Asn Pro Glu Ile
Asn Pro Glu Leu
Asn Pro Ile Glu
Asn Pro Leu Glu
Asn Pro Asn Gln
Asn Pro Gln Asn
Asn Gln Asn Pro
Asn Gln Pro Asn
Asn Ser Asp His
Asn Ser His Asp
Asn Thr His Thr
Asn Thr Thr His
Asn Val Cys His
Asn Val His Cys
Pro Cys Pro Arg
Pro Cys Arg Pro
Pro Asp Ile Gln
Pro Asp Leu Gln
Pro Asp Gln Ile
Pro Asp Gln Leu
Pro Glu Ile Asn
Pro Glu Leu Asn
Pro Glu Asn Ile
Pro Glu Asn Leu
Pro Glu Gln Val
Pro Glu Val Gln
Pro Ile Asp Gln
Pro Ile Glu Asn
Pro Ile Asn Glu
Pro Ile Gln Asp
Pro Met Pro Gln
Pro Met Gln Pro
Pro Asn Asn Gln
Pro Asn Gln Asn
Pro Pro Cys Arg
Pro Pro Met Gln
Pro Pro Gln Met
Pro Pro Arg Cys
Pro Gln Met Pro
Pro Gln Asn Asn
Pro Gln Pro Met
Pro Arg Cys Pro
Pro Arg Pro Cys
Gln Gly His Met
Gln Gly Met His
Gln His Gly Met
Gln His Met Gly
Gln His Ser Thr
Gln His Thr Ser
Gln Met Gly His
Gln Met His Gly
Gln Met Pro Pro
Gln Asn Asn Pro
Gln Asn Pro Asn
Gln Pro Met Pro
Gln Pro Asn Asn
Gln Pro Pro Met
Gln Ser His Thr
Gln Ser Thr His
Gln Thr His Ser
Gln Thr Ser His
Arg Cys Gly His
Arg Cys His Gly
Arg Cys Pro Pro
Arg Gly Cys His
Arg Gly His Cys
Arg His Cys Gly
Arg His Gly Cys
Arg Pro Cys Pro
Arg Pro Pro Cys
Ser Asp His Asn
Ser Asp Asn His
Ser His Asp Asn
Ser His Asn Asp
Ser His Gln Thr
Ser His Thr Gln
Ser Asn Asp His
Ser Asn His Asp
Ser Gln His Thr
Ser Gln Thr His
Ser Thr His Gln
Ser Thr Gln His
Thr His Asn Thr
Thr His Gln Ser
Thr His Ser Gln
Thr His Thr Asn
Thr Asn His Thr
Thr Asn Thr His
Thr Gln His Ser
Thr Gln Ser His
Thr Ser His Gln
Thr Ser Gln His
Thr Thr His Asn
Thr Thr Asn His
Val Cys His Asn
Val Cys Asn His
Val His Cys Asn
Val His Asn Cys
Val Asn Cys His
Val Asn His Cys
MK 886
ETHYL 5-(2,4-BIS(BENZYLOXY)-5-ISOPROPYLPHENYL)ISOXAZOLE-3-CARBOXYLATE
Dimethyl 3,3-({3-acetamido-4-[(E)-(4-nitrophenyl)diazenyl]phenyl }imino)dipropanoate (non-preferred name)
Dorsomorphin 2HCl
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclohexylamino)-2-oxoethyl]-7-methyl-N-(2-methylphenyl)- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclohexylamino)-2-oxoethyl]-7-methyl-N-(3-methylphenyl)- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclohexylamino)-2-oxoethyl]-7-methyl-N-(4-methylphenyl)- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,3-dimethylphenyl)-7-methyl- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,4-dimethylphenyl)-7-methyl- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,5-dimethylphenyl)-6-methyl- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,5-dimethylphenyl)-7-methyl- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2-ethylphenyl)-7-methyl- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(3,5-dimethylphenyl)-7-methyl- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(4-ethylphenyl)-6-methyl- (9CI)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(4-ethylphenyl)-7-methyl- (9CI)
Quinacrine dihydrochloride
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
2,2-[[3-acetamido-4-[(4-nitrophenyl)azo]phenyl]imino]diethyl diacetate
methyl N-[3-(acetylamino)-4-[(4-nitrophenyl)azo]phenyl]-N-(3-methoxy-3-oxopropyl)-beta-alaninate
Muramic acid,N-acetyl-1-O-(phenylmethyl)-4,6-O-(phenylmethylene)- (9CI)
2-[[7-(acetylamino)-6-(benzyloxy)-2-phenylperhydropyrano[3,2-d][1,3]dioxin-8-yl]oxy]propanoic acid
2-amino-N-[5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
LDS 751 dye
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes
Platensimycin A3 Methyl Ester
A polycyclic cage that is the methyl ester derivative of 7-hydroxy substituted platensimycin. It is isolated from Streptomyces platensis.
N-[1-[4-(2-methoxyphenyl)-1-piperazinyl]-1-thiophen-2-ylpropan-2-yl]benzenesulfonamide
4-(2-Hydroxybenzylamino)-N-(3-(4-fluorophenoxy)phenyl)piperidine-1-sulfonamide
2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-YL)ethyl]-4-(4-ethoxy-1,1-biphenyl-4-YL)-4-oxobutanoic acid
Zanubrutinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents D006401 - Hematologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-amino-N-[(2R,3R,4S,5S)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
2-[3a-[1-(furan-3-yl)-5,8a-dimethyl-3-oxo-4,6,7,8-tetrahydro-1H-isochromen-6-yl]-2,2-dimethyl-6-oxo-3,4,7,7a-tetrahydrofuro[3,2-c]pyran-3-yl]acetate
alpha-Neup5Ac-(2->6)-beta-D-Galp
alpha-Neup5Ac-(2->6)-D-Galp in which the anomeric configuration of the reducing-end D-galactose residue is beta.
Ansaetherone
An eleven-membered macrocyclic lactam that consists of (2S,3E,5Z,14S,15R)-5-ethylidene-11,14-dihydroxy-3,7,15-trimethyl-2,5-dihydro-2,13-ethano-1,9-benzoxazacycloundecine-6,8-dione in which the 14-hydroxy group is substituted by a (2R,5R,6R)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl moiety. It is a radical scavenger isolated from Streptomyces.
Scutebarbatine G
A diterpene alkaloid of group of neo-clerodanes isolated from the whole plants of Scutellaria barbata and has been shown to exhibit neoplastic activity.
alpha-Neu5Ac-(2->3)-D-Gal
An amino disaccharide consisting of D-galactose having an alpha-N-acetylneuraminyl residue attached at the 3-position
1-[(4-fluorophenyl)methyl]-4-(3,4,5-trimethoxyphenyl)-4H-pyridine-3,5-dicarboxylic acid dimethyl ester
2-nitro-N-[[4-[(1,2,3,4-tetrahydronaphthalen-2-ylmethylamino)methyl]cyclohexyl]methyl]benzenesulfonamide
2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)-9-purinyl]-4-hydroxy-2-(hydroxymethyl)-3-oxolanyl]-3-(4-methoxyphenyl)propanamide
alpha-Neup5Ac-(2->6)-D-Galp
An amino disaccharide consisting of D-galactose having an alpha-N-acetylneuraminyl residue attached at the 6-position
3-ethyl-2-[(E)-2-[(E)-(3-ethyl-5,6-dimethyl-1,3-benzothiazol-2-ylidene)methyl]but-1-enyl]benzo[g][1,3]benzothiazol-3-ium
3-[2,4-dioxo-1-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-quinazolinyl]-N-(2-furanylmethyl)propanamide
Platensimycin A4 Methyl Ester
A polycyclic cage compound isolated from Streptomyces platensis.
Platensimycin A1 Methyl Ester
A polycyclic cage that is the methyl ester derivative of platensimycin A1. It is isolated from Streptomyces platensis.
Platensimycin A2 Methyl Ester
A polycyclic cage that is the methyl ester derivative of 11-hydroxy substituted platensimycin. It is isolated from Streptomyces platensis.
5-Oxo-2-pyrrolidinecarboxylic acid [2-[3-(4-methoxyphenyl)-5-(2-naphthalenyl)-3,4-dihydropyrazol-2-yl]-2-oxoethyl] ester
(2S)-2-amino-N-[(2S,3S,4R)-5-[6-(dimethylamino)-9-purinyl]-4-hydroxy-2-(hydroxymethyl)-3-oxolanyl]-3-(4-methoxyphenyl)propanamide
(4R,5R)-5-(2-azidophenyl)-2-[4-(3-hydroxypropoxy)phenyl]-4-(phenylmethyl)-5H-oxazole-4-carboxamide
3-O-{5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl}-alpha-D-galactopyranose
3-O-(5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranonosyl)-D-galactopyranose
2-[(2S,3S,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
N-[(5R,6S,9S)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6R,9S)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
2-[(2R,3R,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(3-morpholin-4-ylpropyl)acetamide
(2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
N-[(5R,6S,9R)-5-methoxy-8-(2-methoxyacetyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6R,9R)-5-methoxy-8-(2-methoxyacetyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6R,9S)-5-methoxy-8-(2-methoxyacetyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
2-[(2S,3R,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(3-morpholin-4-ylpropyl)acetamide
2-[(2R,3S,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
(2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
4-[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-5-[[methyl(propyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-8-yl]benzonitrile
(2S)-2-[(4S,5R)-4-methyl-5-[[methyl(propyl)amino]methyl]-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
N-[(5R,6R,9R)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6S,9S)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
2-[(2S,3R,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2R,3R,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
2-[(2R,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2R,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2S,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
[(1S)-7-methoxy-1-[(3-methoxyphenyl)methyl]-2-methylsulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(6R,7S,8S)-8-(hydroxymethyl)-N-(2-methoxyphenyl)-7-[4-(3-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8S)-8-(hydroxymethyl)-N-(2-methoxyphenyl)-7-[4-(3-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
4-[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-5-[[methyl(propyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-8-yl]benzonitrile
4-[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-5-[[methyl(propyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-8-yl]benzonitrile
3-[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-5-[[methyl(propyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-8-yl]benzonitrile
3-[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-5-[[methyl(propyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-8-yl]benzonitrile
N-[(5S,6S,9R)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
2-[(2R,3S,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2S,3S,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
2-[(2S,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2R,5S,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2S,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2R,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
(2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(6S,7S,8R)-8-(hydroxymethyl)-N-(2-methoxyphenyl)-7-[4-(3-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-8-(hydroxymethyl)-N-(2-methoxyphenyl)-7-[4-(3-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
2-[[9-(1-Methylethyl)-6-[[3-(2-pyridinyl)phenyl]amino]-9H-purin-2-yl]amino]-1-butanol hydrochloride hydrate
5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranose
5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-alpha-D-galacto-hexopyranose
(2S)-2-amino-N-[(2S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1,3-dihydroxy-2-methyl-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
(2R,4S,5R,6R)-5-acetamido-2-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
MK886
D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors
alpha-Neup5Ac-(2->3)-beta-D-Galp
An amino disaccharide consisting of beta-D-galactose having an alpha-N-acetylneuraminyl residue attached at the 3-position
alpha-Neup5Ac-(2->3)-alpha-D-GalpNAc
An amino disaccharide comprised of an N-acetyl-alpha-neuraminyl residue linked (2->3) to N-acetyl-alpha-D-galactosamine
Z-Gly-Arg-Thiobenzyl ester
Z-Gly-Arg-Thiobenzyl ester is a chromogenic substrate for plasmogen-activated serine proteases[1].